Profile data is unavailable for this security.
About the company
SciVision Biotech Inc is principally engaged in the manufacturing and distribution of hyaluronic acid medical supplies. The Company primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The Company is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The Company operates its business in the Americas, Europe, Asia, Middle East and Africa.
- Revenue in TWD (TTM)787.96m
- Net income in TWD196.83m
- Incorporated2001
- Employees64.00
- LocationSciVision Biotech IncNo.1, South 1st RoadKAOHSIUNG 806TaiwanTWN
- Phone+886 78232258
- Fax+886 78232295
- Websitehttps://www.scivision.com.tw/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHC Healthcare Group | 3.73bn | 341.88m | 8.95bn | 160.00 | 28.94 | 1.45 | 9.71 | 2.40 | 1.86 | 1.86 | 19.97 | 36.92 | 0.2753 | 4.08 | 3.97 | -- | 2.52 | 3.23 | 3.00 | 3.80 | 26.37 | 30.12 | 9.15 | 13.16 | 2.01 | 10.78 | 0.455 | 81.75 | 30.35 | 9.11 | 17.47 | 5.31 | 9.69 | 2.25 |
| SciVision Biotech Inc | 787.96m | 196.83m | 9.08bn | 64.00 | 49.73 | 5.87 | 34.92 | 11.53 | 2.67 | 2.67 | 10.33 | 22.67 | 0.3601 | 2.14 | 8.34 | -- | 9.00 | 6.67 | 10.09 | 7.41 | 74.13 | 69.94 | 24.98 | 25.00 | 2.90 | -- | 0.1739 | 79.74 | 27.93 | 16.69 | 25.53 | 15.41 | -31.16 | 12.22 |
Data as of Jun 28 2024. Currency figures normalised to SciVision Biotech Inc's reporting currency: Taiwan Dollar TWD
0.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 06 Jun 2024 | 151.00k | 0.22% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 143.00k | 0.21% |
| Dimensional Fund Advisors Ltd.as of 30 Apr 2024 | 7.00k | 0.01% |
| American Century Investment Management, Inc.as of 06 Jun 2024 | 1.00k | 0.00% |
| DFA Australia Ltd.as of 30 Apr 2024 | 612.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 20 Jun 2024Source: FactSet Research Systems Inc.
